NCp7: targeting a multitask protein for next-generation anti-HIV drug development part 2. Noncovalent inhibitors and nucleic acid binders.

Nunzio Iraci, Oriana Tabarrini, Claudio Santi, Luca Sancineto

Journal: Drug discovery today 2018;23(3):687-695

PMID: 29326078

Full Text on Elsevier Science View on PubMed

Abstract

Nucleocapsid protein 7 (NCp7) represents a viable target not yet reached by the currently available antiretrovirals. It is a small and highly basic protein, which is essential for multiple stages of the viral replicative cycle, with its structure preserved in all viral strains, including clinical isolates. NCp7 can be inhibited covalently, noncovalently and by shielding the nucleic acid (NA) substrates of its chaperone activity. Although covalent NCp7 inhibitors have already been detailed in the first part of this review series, the focus here is based on noncovalent and NA-binder inhibitors and on the analysis of the NCp7 3D structure to deliver fruitful insights for future drug design strategies.

Address: Department of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.; Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.; Department of Heterorganic Chemistry, Centre of Molecular and Macromulecular Studies, Lodz, Poland. Electronic address: [email protected].

DOI: 10.1016/j.drudis.2018.01.022

Link outs

Free resources

Medical:

https://medlineplus.gov/hivmedicines.html

Other Literature Sources:

https://scite.ai/reports/29326078

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1359...

MeSH Terms: Amino Acid Sequence, Anti-HIV Agents, Humans, Nucleic Acids, Nucleocapsid Proteins, Protein Binding, Viral Proteins, Virus Replication